These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 12803925)

  • 1. Enzyme replacement therapy: conception, chaos and culmination.
    Brady RO
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):915-9. PubMed ID: 12803925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice.
    Sly WS
    Mo Med; 2004; 101(2):100-4. PubMed ID: 15119106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigations in enzyme replacement therapy in lipid storage diseases.
    Brady RO; Pentchev PG; Gal AG
    Fed Proc; 1975 Apr; 34(5):1310-5. PubMed ID: 804420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances and novel treatments for sphingolipidoses.
    Arenz C
    Future Med Chem; 2017 Sep; 9(14):1687-1700. PubMed ID: 28857617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement for lysosomal diseases.
    Brady RO
    Annu Rev Med; 2006; 57():283-96. PubMed ID: 16409150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.
    Desnick RJ; Schuchman EH
    Nat Rev Genet; 2002 Dec; 3(12):954-66. PubMed ID: 12459725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the biochemistry and genetics of sphingolipidoses.
    Ozkara HA
    Brain Dev; 2004 Dec; 26(8):497-505. PubMed ID: 15533650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An appraisal of human trials in enzyme replacement therapy of genetic diseases.
    Tager JM; Hamers MN; Schram AW; Van den Bergh FA; Rietra PJ; Loonen C; Koster JF; Slee R
    Birth Defects Orig Artic Ser; 1980; 16(1):343-59. PubMed ID: 6778527
    [No Abstract]   [Full Text] [Related]  

  • 10. [Phenotypes in heteroglycanoses and sphingolipidoses (author's transl)].
    Gehler J
    Monatsschr Kinderheilkd; 1981 Nov; 129(11):610-20. PubMed ID: 6798422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model.
    Kesselman I; Elstein D; Israeli A; Chertkoff R; Zimran A
    Blood Cells Mol Dis; 2006; 37(1):46-9. PubMed ID: 16824774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular facets of sphingolipids: mediators of diseases.
    Ozbayraktar FB; Ulgen KO
    Biotechnol J; 2009 Jul; 4(7):1028-41. PubMed ID: 19579220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Musculoskeletal complications encountered in the lysosomal storage disorders.
    Pastores GM
    Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):937-47. PubMed ID: 19028373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease.
    Di Rocco M; Giona F; Carubbi F; Linari S; Minichilli F; Brady RO; Mariani G; Cappellini MD
    Haematologica; 2008 Aug; 93(8):1211-8. PubMed ID: 18603565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.
    Muro S; Schuchman EH; Muzykantov VR
    Mol Ther; 2006 Jan; 13(1):135-41. PubMed ID: 16153895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural aspects of therapeutic enzymes to treat metabolic disorders.
    Kang TS; Stevens RC
    Hum Mutat; 2009 Dec; 30(12):1591-610. PubMed ID: 19790257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments.
    Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y
    Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The methods of therapy in geneticaly determined storage diseases (author's transl)].
    Gniot-Szulzycka J
    Przegl Lek; 1976; 33(12):984-91. PubMed ID: 827789
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative evaluation of sphingomyelin and glucosylceramide using matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard. Practical application to tissues from patients with Niemann-Pick disease types A and C, and Gaucher disease.
    Fujiwaki T; Tasaka M; Yamaguchi S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(2):170-6. PubMed ID: 18502707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.